Simple Summary NTRK fusion genes are important but not well studied molecular markers
in thyroid cancer. Their identification could help improve diagnosis and prognosis, and …

Objective PTC-specific analysis identified novel fusions involving RET, BRAF, NTRK1,
NTRK3, AGK and ALK genes in adults and pediatric PTCs. Although many novel fusions are …

NTRK1/3 rearrangements have been reported in 2.3–3.4% of papillary thyroid carcinoma
(PTC) and are regarded as potential therapeutic targets. Recently, the application of …

BACKGROUND An increase in thyroid cancers, predominantly papillary thyroid carcinoma
(PTC), has been recently reported in children. METHODS The histopathology of 28 …

Primary thyroid neoplasms with actionable NTRK rearrangements are rare, and their clinical
behavior, histologic characteristics, and molecular landscape are not well understood. We …

Background: Pediatric papillary thyroid carcinoma (PTC) is a rare malignancy, but with
increasing incidence. Pediatric PTCs have distinct clinical and pathological features and …

Background Larotrectinib is a first-in-class, central nervous system-active, highly selective
tropomyosin receptor kinase (TRK) inhibitor approved by the EMA and FDA for the treatment …

Objective Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor with
demonstrated efficacy across various TRK fusion-positive solid tumours. We assessed the …

TRK oncogenes are observed in a consistent fraction of papillary thyroid carcinoma (PTC);
they arise from the fusion of the 3′ terminal sequences of the NTRK1/NGF receptor gene …

The NTRK genes include a family of three genes, NTRK1, NTRK2, and NTRK3, which are
associated with fusions with a variety of partner genes, leading to upregulation of three …